首页> 外文期刊>Therapeutic Drug Monitoring >Distinction of inhaled and oral salbutamol by urine analysis using conventional screening procedures for doping control.
【24h】

Distinction of inhaled and oral salbutamol by urine analysis using conventional screening procedures for doping control.

机译:吸入和口服沙丁胺醇通过尿液分析进行区分,使用常规的筛查程序进行掺杂控制。

获取原文
获取原文并翻译 | 示例
           

摘要

Salbutamol administration in athletes is permitted only by inhalation, for the management of asthma. The authors discuss different criteria for suspecting oral use of salbutamol, taking into account the data obtained by application of two conventional screening procedures for doping control: gas chromatography/mass spectrometry (GC/MS) and enzyme-linked immunosorbent assay (ELISA). Urine samples obtained after administration of oral and inhaled salbutamol to asthmatic and nonasthmatic swimmers were analyzed using both analytical approaches. As expected, concentrations obtained by the ELISA test (detection of total salbutamol) were higher than those obtained using the GC/MS procedure (detection of nonsulfated salbutamol). After oral administration, the ELISA test detected significantly higher salbutamol concentrations than those detected after inhalation, reflecting the greater doses administered orally. Urine samples with total salbutamol greater than 1400 ng/mL were obtained after oral doses, but no sample reached this value after inhaled doses. Higher concentrations of nonsulfated salbutamol have also been detected after oral intake, although there is an overlap between the distributions of concentrations after oral and inhaled doses. A cut-off concentration of 500 ng/mL can be used for nonsulfated salbutamol to select suspicious samples, giving 11.8% false negative results and 4.3% false positive results. An additional criterion evaluated was the androsterone-salbutamol peak height ratio, which was lower after oral doses because of the higher concentrations of salbutamol in urine. This ratio was lower than 2 for all the samples collected after oral administration, although 6.8% false positive samples resulted because of low concentrations of androsterone in female urine. Several possibilities for detecting suspicious samples from athletes who have taken prohibited oral salbutamol are available with conventional screening procedures in doping control.
机译:沙丁胺醇在运动员中的给药只能通过吸入进行,以控制哮喘。考虑到通过应用两种常规筛查程序进行掺杂控制所获得的数据,作者讨论了怀疑可口服沙丁胺醇的不同标准:气相色谱/质谱(GC / MS)和酶联免疫吸附测定(ELISA)。使用两种分析方法分析了向哮喘和非哮喘游泳者口服和吸入沙丁胺醇后的尿液样品。正如预期的那样,通过ELISA测试获得的浓度(检测总沙丁胺醇)高于使用GC / MS方法获得的浓度(检测未硫酸化的沙丁胺醇)。口服后,ELISA试验检测到的沙丁胺醇浓度明显高于吸入后的浓度,反映出口服剂量更大。口服剂量后可获得总沙丁胺醇大于1400 ng / mL的尿液样品,但吸入剂量后没有样品达到该值。口服后吸入的非硫酸沙丁胺醇浓度也较高,尽管口服和吸入剂量后的浓度分布重叠。非硫酸沙丁胺醇的截断浓度为500 ng / mL,可用于选择可疑样品,假阴性结果为11.8%,假阳性结果为4.3%。评估的另一个标准是雄激素-沙丁胺醇的峰高比,口服后较低,因为尿液中沙丁胺醇的浓度较高。对于口服给药后收集的所有样品,该比率均低于2,尽管由于女性尿液中雄甾酮的浓度较低而导致产生6.8%的假阳性样品。在兴奋剂控制中,可采用常规的筛查程序从检测了服用违禁口服沙丁胺醇的运动员中检测可疑样品的几种可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号